Masitinib - A targeted therapy with applications in veterinary oncology and inflammatory diseases

CAB Reviews: Perspectives in Agriculture, Veterinary Science, Nutrition and Natural Resources

Volumn 6, Issue , 2011, Pages

  Ogilvie, G K ^a   Hensel, P ^b   Kitchell, B E ^c   Dubreuil, P ^d,e,f   Ahn, A ^g  

^a California Veterinary Specialists   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

^c MICHIGAN STATE UNIVERSITY   (United States)

^d AIX MARSEILLE UNIVERSITY   (France)

^e INSTITUT PAOLI CALMETTES   (France)

^f AIX MARSEILLE UNIVERSITY   (France)

^g AB Science USA ^*  (United States)

Author keywords

Atopic dermatitis; Cancer; Inflammatory disease; Masitinib; Mast cell tumour; Protein kinase inhibitor; Tyrosine kinase inhibitor

Indexed keywords

CANIS FAMILIARIS; FELIDAE;

EID: 80052503974     PISSN: None     EISSN: 17498848     Source Type: Journal    
DOI: 10.1079/PAVSNNR20110021     Document Type: Review

References (53)

1. Dubreuil P, Letard S, Ciufolini M, Gros L, Humbert M, Casteran N, et al. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS One 2009;4:e7258.
2. Hahn KA, Legendre AM, Shaw NG, Phillips B, Ogilvie GK, Prescott DM, et al. Evaluation of 12-and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors. American Journal of Veterinary Research 2010;71:1354-61.
3. Hahn KA, Ogilvie G, Rusk T, Devauchelle P, Leblanc A, Legendre A, et al. Masitinib is safe and effective for the treatment of canine mast cell tumors. Journal of Veterinary Internal Medicine 2008;22:1301-9.
4. Cadot P, Hensel P, Bensignor E, Hadjaje C, Marignac G, Beco L, et al. Masitinib decreases signs of canine atopic dermatitis: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Veterinary Dermatology 2011;22:doi: 10.1111/j.1365-3164.2011.00990.x.
5. Humbert M, de Blay F, Garcia G, Prud'homme A, Leroyer C, Magnan A, et al. Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics. Allergy 2009;64:1194-201.
6. Soria JC, Massard C, Magne N, Bader T, Mansfield CD, Blay JY, et al. Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers. European Journal of Cancer 2009;45:2333-41.
7. Tebib J, Mariette X, Bourgeois P, Flipo RM, Gaudin P, Le Loet X, et al. Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study. Arthritis Research and Therapy 2009;11:R95.
8. Humbert M, Casteran N, Letard S, Hanssens K, Iovanna J, Finetti P, et al. Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model. PLoS One 2010;5:e9430.
9. Le Cesne A, Blay JY, Bui BN, Bouche O, Adenis A, Domont J, et al. Phase II study of oral masitinib mesilate in imatinib-naive patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST). European Journal of Cancer 2010;46:1344-51.
10. Mitry E, Hammel P, Deplanque G, Mornex F, Levy P, Seitz JF, et al. Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology 2010;66:395-403.
11. Paul C, Sans B, Suarez F, Casassus P, Barete S, Lanternier F, et al. Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: A phase 2a study. American Journal of Hematology 2010;85:921-5.
12. Piette F, Belmin J, Vincent H, Schmidt N, Pariel S, Verny M, et al. Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial. Alzheimer's Research and Therapy 2011;3:16.
13. Reber L, Da Silva CA, Frossard N. Stem cell factor and its receptor c-Kit as targets for inflammatory diseases. European Journal of Pharmacology 2006;533:327-40. (Pubitemid 43340024)
14. Sum SO, Hensel P, Rios L, Brown S, Howerth EW, Driskell EA, et al. Drug-induced minimal change nephropathy in a dog. Journal of Veterinary Internal Medicine 2010;24:431-5.
15. Force T, Kerkela R. Cardiotoxicity of the new cancer therapeutics - mechanisms of, and approaches to, the problem. Drug Discovery Today 2008;13:778-84.
16. Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nature Reviews Cancer 2007;7:332-44. (Pubitemid 46652481)
17. Francis J, Ahluwalia MS, Wetzler M, Wang E, Paplham P, Smiley S, et al. Reversible cardiotoxicity with tyrosine kinase inhibitors. Clinical Advances in Hematology and Oncology 2010;8:128-32.
18. Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nature Medicine 2006;12:908-16. (Pubitemid 44175142)
19. Kerkela R, Woulfe KC, Durand JB, Vagnozzi R, Kramer D, Chu TF et al. Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clinical and Translational Science 2009;2:15-25.
20. Trent JC, Patel SS, Zhang J, Araujo DM, Plana JC, Lenihan DJ, et al. Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate. Cancer 2009;116:184-92.
21. Wolf A, Couttet P, Dong M, Grenet O, Heron M, Junker U, et al. Imatinib does not induce cardiotoxicity at clinically relevant concentrations in preclinical studies. Leukemia Research 2010;34:1180-8.
22. Huang B, Lei Z, Zhang GM, Li D, Song C, Li B, et al. SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment. Blood 2008;112:1269-79.
23. Soucek L, Lawlor ER, Soto D, Shchors K, Swigart LB, Evan GI. Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nature Medicine 2007;13:1211-8. (Pubitemid 47530639)
24. Theoharides TC. Mast cells and pancreatic cancer. New England Journal of Medicine 2008;358:1860-1. (Pubitemid 351581204)
25. Vacca A, Ribatti D, Roccaro AM, Frigeri A, Dammacco F. Bone marrow angiogenesis in patients with active multiple myeloma. Seminars in Oncology 2001;28:543-50. (Pubitemid 33134413)
26. Nakayama T, Yao L, Tosato G. Mast cell-derived angiopoietin-1 plays a critical role in the growth of plasma cell tumors. Journal of Clinical Investigation 2004;114:1317-25. (Pubitemid 40385303)
27. Beaven MA. Our perception of the mast cell from Paul Ehrlich to now. European Journal of Immunology 2009;39:11-25.
28. Gilfillan AM, Rivera J. The tyrosine kinase network regulating mast cell activation. Immunological Reviews 2009;228:149-69.
29. Gilfillan AM, Tkaczyk C. Integrated signalling pathways for mast-cell activation. Nature Reviews Immunology 2006;6:218-30. (Pubitemid 43290991)
30. Jayson G, Armand JP, Berdel WE. Inhibition of angiogenesis by proteins, peptides and "small molecules". Onkologie 2005;28(Suppl. 4):29-34. (Pubitemid 44699454)
31. Guan H, Zhou Z, Gallick GE, Jia SF, Morales J, Sood AK, et al. Targeting Lyn inhibits tumor growth and metastasis in Ewing's sarcoma. Molecular Cancer Therapeutics 2008;7:1807-16.
32. Wu J, Meng F, Kong LY, Peng Z, Ying Y, Bornmann WG, et al. Association between imatinib-resistant BCR-ABL mutationnegative leukemia and persistent activation of LYN kinase. Journal of the National Cancer Institute 2008;100:926-39. (Pubitemid 351957515)
33. Hermine O. Impact of masitinib on metastatic mast cell tumors and on the emergence of metastasis from non-metastatic tumors. In: Proceedings of the 29th Annual Conference of the Veterinary Cancer Society, 16-19 October 2009, Austin, TX, USA; 2009.
34. Phillips B, Legendre A, Shaw N, Ahn A. Fifty months and counting: Case studies exemplifying the long-term survival of masitinib in dogs with non-resectable grade II mast cell tumors. In: Proceedings of the 30th Annual Conference of the Veterinary Cancer Society, 29 October-1 November 2010, San Diego, CA, USA; 2010.
35. de Vos J, Brearley M. Targeted therapy with masitinib in canine and feline tumours in two European veterinary oncology centres. In: Proceedings of the Mid-Year Conference of the Veterinary Cancer Society, 7-10 March 2010, Las Vegas, USA; 2010.
36. Serres F, Meyer C, Tierny D, Hidalgo A, Haelewyn C, Marescaux L. Masitinib for maintenance chemotherapy of 2 dogs with T cell multicentric lymphoma. In: Proceedings of the European Society of Veterinary Oncology Spring Congress, 18-20 March 2010, Turin, Italy; 2010.
37. Jagielski D, Chapuis T, Lebruneau J, Hermine O. Positive response in the treatment of epitheliotropic T-cell lymphoma (mycosis fungoides) with masitinib. In: Proceedings of the Annual Congress of the European Society of Veterinary Oncology, 24-26 March 2011, Glasgow, UK; 2011.
38. Thamm DH, Rose B, Kow KY, Humbert M, Moussy A, Hermine O, et al. Masitinib is a chemosensitiser of canine tumor cell lines. In: Proceedings of the 28th Annual Conference of the Veterinary Cancer Society, 18-21 October 2008; Seattle, USA; 2008.
39. ®) shows therapeutic potential in dog neurofibrosarcoma. In: Proceedings of the Annual Congress of the European Society of Veterinary Oncology, 18-20 March 2010, Turin, Italy; 2010.
40. Badache A, De Vries GH. Neurofibrosarcoma-derived Schwann cells overexpress platelet-derived growth factor (PDGF) receptors and are induced to proliferate by PDGF BB. Journal of Cellular Physiology 1998;177:334-42. (Pubitemid 28452834)
41. Viskochil DH. It takes two to tango: mast cell and Schwann cell interactions in neurofibromas. Journal of Clinical Investigation 2003;112:1791-3. (Pubitemid 38063701)
42. Thamm D, Rose B, Kow K, Humbert M, Mansfield CD, Moussy A, et al. Masitinib as a chemosensitiser of canine tumor cell lines: a proof of concept study. Veterinary Journal 2011; doi:10.1016/j.tvjl.2011.01.001.
43. Ogilvie G, Rusk A, Legendre A, Moussy A, Hermine O. Evaluation of safety of masitinib in combination with doxorubicin in advanced canine tumors. In: Proceedings of the Mid-Year Conference of the Veterinary Cancer Society, 7-10 March 2010, Las Vegas, USA; 2010.
44. Ogilvie G, Rusk A, Legendre A, Moussy A, Hermine O. Evaluation of safety of masitinib in combination with carboplatin in advanced canine tumors. In: Proceedings of the Mid-Year Conference of the Veterinary Cancer Society, 7-10 March 2010, Las Vegas, USA; 2010.
45. Kinet JP. The essential role of mast cells in orchestrating inflammation. Immunological Reviews 2007;217:5-7.
46. Daigle J, Moussy A, Mansfield CD, Hermine O. Masitinib for the treatment of canine atopic dermatitis: a pilot study. Veterinary Research Communications 2009;34:51-63.
47. Reinero CR, Cohn LA, Delgado C, Spinka CM, Schooley EK, DeClue AE. Adjuvanted rush immunotherapy using CpG oligodeoxynucleotides in experimental feline allergic asthma. Veterinary Immunology and Immunopathology 2008;121:241-50. (Pubitemid 351163398)
48. Janeczko S, Atwater D, Bogel E, Greiter-Wilke A, Gerold A, Baumgart M, et al. The relationship of mucosal bacteria to duodenal histopathology, cytokine mRNA, and clinical disease activity in cats with inflammatory bowel disease. Veterinary Microbiology 2008;128:178-93. (Pubitemid 351192258)
49. Rassnick KM, Williams LE, Kristal O, Al-Sarraf R, Baez JL, Zwahlen CH, et al. Lomustine for treatment of mast cell tumors in cats: 38 cases (1999-2005). Journal of the American Veterinary Medical Association 2008;232:1200-5. (Pubitemid 351654626)
50. Bellamy F, Bader T, Moussy A, Hermine O. Pharmacokinetics of masitinib in cats. Veterinary Research Communications 2009;33:831-7.
51. Daly M, Sheppard S, Cohen N, Nabity M, Moussy A, Hermine O, et al. Safety of masitinib mesylate in healthy cats. Journal of Veterinary Internal Medicine 2011;25(2):297-302.
52. Lee-Fowlera T, Gunturb V, Dodama J, Cohna L, DeCluea A, Reineroa C. A randomised, blinded, placebo-controlled study of the tyrosine kinase inhibitor masitinib for treatment of experimental feline asthma. In: Proceedings of the 28th Veterinary Comparative Respiratory Symposium in Raleigh, 28-30 September 2010, Raleigh, NC, USA; 2010.
53. Daly M, Sheppard S, Huelsmeyer M, Wilson H. Evaluation of the receptor tyrosine kinase inhibitor, masitinib mesylate, in feline vaccine associated sarcoma cell lines and healthy cats. In: Proceedings of the 29th Annual Conference of the Veterinary Cancer Society, 16-19 October 2009, Austin, Texas, USA; 2009.